How to buy Illumina (ILMN) shares in Australia

Learn how to easily invest in Illumina shares.

Illumina Inc
NASDAQ: ILMN - USD
DIAGNOSTICS & RESEARCH
$409.93
+ $1.83 ( + 0.45%)

We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!

Illumina Inc (ILMN) is a leading diagnostics & research business with stocks listed in the US. It opened the day at US$461.54 after a previous close of US$459.25. During the day the price has varied from a low of USD457.78 to a high of USD465.59. The latest price was USD458.21 (25 minute delay). Illumina is listed on the NASDAQ. All prices are listed in US Dollars.

How to buy shares in Illumina

  1. Compare share trading platforms. To buy shares in a US company from Australia you'll need to find a trading platform that offers access to US stock markets. If you're just starting out, look for a platform with low brokerage and foreign exchange fees.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and tax file number. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Illumina. Find the share by name or ticker symbol: ILMN. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Illumina reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of US$459.25, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs. You may be able to buy a fractional share of Illumina, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Illumina. Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Illumina stock price (NASDAQ:ILMN)

Use our graph to track the performance of ILMN stocks over time.

Illumina shares at a glance

Information last updated 2021-09-10.
OpenUS$461.54
HighUS$465.59
LowUS$457.78
CloseUS$458.21
Previous closeUS$459.25
Change US$-1.04
Change % -0.2265%
Volume 444,215
Information last updated 2021-10-08.
52-week rangeUS$288.01 - US$526
50-day moving average US$442.8824
200-day moving average US$439.359
Target priceUS$453.31
PE ratio 78.514
Dividend yield N/A (0%)
Earnings per share (TTM) US$5.222

Where to buy Illumina stock

Name Product Standard brokerage for US shares Currency conversion fee Markets
eToro (global stocks)
US$0
50 pips (US$0.50 for every AU$100 exchanged)
Global shares, US shares, ETFs
Zero brokerage share trading on US, Hong Kong and European stocks with trades as low as $50.
Note: This broker offers CFDs which are volatile investment products and most clients lose money trading CFDs with this provider.
Join the world’s biggest social trading network when you trade stocks, commodities and currencies from the one account.
IG Share Trading
US$0
0.70%
ASX shares, Global shares
$0 brokerage for US and global shares plus get an active trader discount of $5 commission on Australian shares.
Enjoy some of the lowest brokerage fees on the market when trading Australian shares, international shares, plus get access to 24-hour customer support.
Superhero share trading
US$0
50 pips (US$0.50 for every AU$100 exchanged)
ASX shares, US shares
Australia’s lowest-cost broker for ASX shares and ETFs.
Pay zero brokerage on US stocks and all ETFs and just $5 (flat fee) to trade Australian shares from your mobile or desktop.
SelfWealth (Basic account)
US$9.5
0.60%
ASX shares, US shares
Trade ASX and US shares for a flat fee of $9.50, regardless of the trade size.
New customers receive free access to Community Insights with SelfWealth Premium for the first 90 days. Follow other investors and benchmark your portfolio performance.
Saxo Capital Markets (Classic account)
US$4
1%
ASX shares, Global shares, Forex, CFDs, Margin trading, Options trading, ETFs
Access 19,000+ stocks on 40+ exchanges worldwide
Low fees for Australian and global share trading, no inactivity fees, low currency conversion fee and optimised for mobile.
CMC Markets Invest
US$0
0.60%
ASX shares, Global shares, mFunds, ETFs
$0 brokerage on global shares including US, UK and Japan markets.
Trade up to 9,000 products, including shares, ETFs and managed funds, plus access up to 15 major global and Australian stock exchanges.
loading

Compare up to 4 providers

The value of your investments can fall as well as rise and you may get back less than you invested. Past performance is no indication of future results.

Is it a good time to buy Illumina stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Illumina share growth calculator

US$

Use the fields above to explore the returns from a historical investment. Please refer to the charts further up this page to see performance over 5 years, or other periods. Past performance doesn't indicate future results. Capital is at risk.

Considering buying Illumina shares?

Before you consider Illumina, you'll want to hear this.
Ticker Nerd uses advanced software to track hundreds of signals and data points to find stocks before they blow up. You can get the next two hot stocks they find sent to your inbox for free.

Show me how

Illumina price performance over time

Historical closes compared with the last close of $458.21

1 week (2021-10-08) 11.76%
1 month (2021-09-15) 1.85%
3 months (2021-07-15) -0.93%
6 months (2021-04-15) 13.99%
1 year (2020-10-15) 41.52%
2 years (2019-10-15) 46.78%
3 years (2018-10-15) 46.20%
5 years (2016-10-14) 232.04%

Is Illumina under- or over-valued?

Valuing Illumina stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Illumina's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Illumina's P/E ratio

Illumina's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 79x. In other words, Illumina shares trade at around 79x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

Illumina's PEG ratio

Illumina's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.4485. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Illumina's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Illumina's EBITDA

Illumina's EBITDA (earnings before interest, taxes, depreciation and amortisation) is US$843 million (£0.0 million).

The EBITDA is a measure of a Illumina's overall financial performance and is widely used to measure a its profitability.

Illumina financials

Revenue TTM US$4 billion
Operating margin TTM 16.36%
Gross profit TTM US$2.2 billion
Return on assets TTM 5.1%
Return on equity TTM 15.79%
Profit margin 19.39%
Book value 35.238
Market capitalisation US$64.2 billion

TTM: trailing 12 months

Shorting Illumina shares

There are currently 2.4 million Illumina shares held short by investors – that's known as Illumina's "short interest". This figure is 10.6% up from 2.2 million last month.

There are a few different ways that this level of interest in shorting Illumina shares can be evaluated.

Illumina's "short interest ratio" (SIR)

Illumina's "short interest ratio" (SIR) is the quantity of Illumina shares currently shorted divided by the average quantity of Illumina shares traded daily (recently around 825369.3877551). Illumina's SIR currently stands at 2.94. In other words for every 100,000 Illumina shares traded daily on the market, roughly 2940 shares are currently held short.

However Illumina's short interest can also be evaluated against the total number of Illumina shares, or, against the total number of tradable Illumina shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Illumina's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Illumina shares in existence, roughly 20 shares are currently held short) or 0.0166% of the tradable shares (for every 100,000 tradable Illumina shares, roughly 17 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Illumina.

Find out more about how you can short Illumina stock.

Illumina's environmental, social and governance track record

Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Illumina.

When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.

Illumina's total ESG risk score

Total ESG risk: 9.18

Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Illumina's overall score of 9.18 (as at 12/31/2018) is excellent – landing it in it in the 2nd percentile of companies rated in the same sector.

ESG scores are increasingly used to estimate the level of risk a company like Illumina is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).

Illumina's environmental score

Environmental score: 2.22/100

Illumina's environmental score of 2.22 puts it squarely in the 2nd percentile of companies rated in the same sector. This could suggest that Illumina is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.

Illumina's social score

Social score: 2.6/100

Illumina's social score of 2.6 puts it squarely in the 2nd percentile of companies rated in the same sector. This could suggest that Illumina is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.

Illumina's governance score

Governance score: 5.36/100

Illumina's governance score puts it squarely in the 2nd percentile of companies rated in the same sector. That could suggest that Illumina is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.

Illumina's controversy score

Controversy score: 1/5

ESG scores also evaluate any incidences of controversy that a company has been involved in. Illumina scored a 1 out of 5 for controversy – the highest score possible, reflecting that Illumina has managed to keep its nose clean.

Environmental, social, and governance (ESG) summary

Illumina Inc was last rated for ESG on: 2019-01-01.

Total ESG score 9.18
Total ESG percentile 2.42
Environmental score 2.22
Environmental score percentile 2
Social score 2.6
Social score percentile 2
Governance score 5.36
Governance score percentile 2
Level of controversy 1

Illumina share dividends

We're not expecting Illumina to pay a dividend over the next 12 months.

Have Illumina's shares ever split?

Illumina's shares were split on a 2:1 basis on 22 September 2008. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Illumina shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Illumina shares which in turn could have impacted Illumina's share price.

Illumina share price volatility

Over the last 12 months, Illumina's shares have ranged in value from as little as US$288.01 up to US$526. A popular way to gauge a stock's volatility is its "beta".

ILMN.US volatility(beta: 0.95)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Illumina's is 0.9529. This would suggest that Illumina's shares are less volatile than average (for this exchange).

Illumina overview

Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. It has collaboration agreements with Geneseeq Technology Inc. to develop comprehensive in-vitro diagnostic (IVD) NGS testing kits for cancer; LetsGetChecked to track COVID-19 variants in California; and Merck & Co., Inc. to develop and commercialize tests that identify genetic mutations used in the assessment of homologous recombination deficiency. The company was incorporated in 1998 and is headquartered in San Diego, California.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com.au:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com.au is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder only provides general advice and factual information, so consider your own circumstances, or seek advice before you decide to act on our content. By submitting a question, you're accepting our Terms of Use, Disclaimer & Privacy Policy and Privacy & Cookies Policy.
Go to site